Akcea Therapeutics Inc (AKCA) Forecast, Price Target & Analyst Ratings
NASDAQ:AKCA
Current stock price
18.17
+0.03 (+0.17%)
At close:
18.15
-0.02 (-0.11%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Akcea Therapeutics Inc (AKCA).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $18.17 to mean target of N/A, Based on 3 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
60.00%
AKCA was analyzed by 3 analysts. The buy percentage consensus is at 60. So analysts seem to be rather neutral about AKCA.
In the last month the buy percentage fell by 10 points. So the trust of analysts is decreasing.
Only 3 analysts analyzed AKCA. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A